Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors

被引:89
|
作者
Young, MB
Barrow, JC
Glass, KL
Lundell, GF
Newton, CL
Pellicore, JM
Rittle, KE
Selnick, HG
Stauffer, KJ
Vacca, JP
Williams, PD
Bohn, D
Clayton, FC
Cook, JJ
Krueger, JA
Kuo, LC
Lewis, SD
Lucas, BJ
McMasters, DR
Miller-Stein, C
Pietrak, BL
Wallace, AA
White, RB
Wong, B
Yan, YW
Nantermet, PG
机构
[1] Merck & Co Inc, Merck Res Labs, Med Chem, West Point, PA 19486 USA
[2] Merck & Co Inc, Merck Res Labs, Pharmacol, West Point, PA 19486 USA
[3] Merck & Co Inc, Merck Res Labs, Biol Chem, West Point, PA 19486 USA
[4] Merck & Co Inc, Merck Res Labs, Struct Biol, West Point, PA 19486 USA
[5] Merck & Co Inc, Merck Res Labs, Mol Syst, West Point, PA 19486 USA
[6] Merck & Co Inc, Merck Res Labs, Drug Metab, West Point, PA 19486 USA
关键词
D O I
10.1021/jm030303e
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In an effort to discover potent, clinically useful thrombin inhibitors, a rapid analogue synthetic approach was used to explore the P-1 region. Various benzylamines were coupled to a pyridine/pyrazinone P-2-P-3 template. One compound with an o-thiadiazole benzylic substitution was found to have a thrombin K-i of 0.84 nM. A study of ortho-substituted five-membered-ring heterocycles was undertaken and subsequently demonstrated that the o-triazole and tetrazole rings were optimal. Combination of these potent P-1 aryl heterocycles with a variety of P-2-P-3 groups produced a compound with an extraordinary thrombin inhibitory activity of 1.4 pM. It is hoped that this potency enhancement in P-1 will allow for more diversification in the P-2-P-3 region to ultimately address additional pharmacological concerns.
引用
收藏
页码:2995 / 3008
页数:14
相关论文
共 50 条
  • [21] The discovery of potent and selective peptidomimetic inhibitors of thrombin.
    Cody, WL
    Berryman, KA
    Cai, C
    Doherty, AM
    Edmunds, JJ
    He, JX
    Holland, DR
    Narasimhan, L
    Plummer, JS
    Rapundalo, ST
    Susser, A
    VanHuis, CA
    Siddiqui, MA
    St-Denis, Y
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1999, 217 : U1178 - U1178
  • [22] Heterocycle-Based Multicomponent Reactions in Drug Discovery: From Hit Finding to Rational Design
    Nadal Rodriguez, Pau
    Ghashghaei, Ouldouz
    Bagan, Andrea
    Escolano, Carmen
    Lavilla, Rodolfo
    BIOMEDICINES, 2022, 10 (07)
  • [23] Novel BACE1 inhibitors with a non-acidic heterocycle at the P1′ position
    Suzuki, Kenji
    Hamada, Yoshio
    Nguyen, Jeffrey-Tri
    Kiso, Yoshiaki
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (21) : 6665 - 6673
  • [24] New, potent P1/P2-morpholinone-based HIV-protease inhibitors
    Kazmierski, Wieslaw M.
    Furfine, Eric
    Spaltenstein, Andrew
    Wright, Lois L.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (19) : 5226 - 5230
  • [25] Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties
    Pinto, Donald J. P.
    Galemmo, Robert A., Jr.
    Quan, Mimi L.
    Orwat, Michael J.
    Clark, Charles
    Li, Renhua
    Wells, Brian
    Woerner, Francis
    Alexander, Richard S.
    Rossi, Karen A.
    Smallwood, Angela
    Wong, Pancras C.
    Luettgen, Joseph M.
    Rendina, Alan R.
    Knabb, Robert M.
    He, Kan
    Wexler, Ruth R.
    Lam, Patrick Y. S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (21) : 5584 - 5589
  • [26] Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385
    Miller, JF
    Andrews, CW
    Brieger, M
    Furfine, ES
    Hale, MR
    Hanlon, MH
    Hazen, RJ
    Kaldor, I
    McLean, EW
    Reynolds, D
    Sarnmond, DM
    Spaltenstein, A
    Tung, R
    Turner, EM
    Xu, RX
    Sherrill, RG
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (07) : 1788 - 1794
  • [27] Aromatic heterocycle-based DPP-IV inhibitors: Xanthines and related structural types
    Szczepankiewicz, Bruce G.
    Kurukulasuriya, Ravi
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2007, 7 (06) : 569 - 578
  • [28] Potent and selective aggrecanase inhibitors containing cyclic P1 substituents
    Cherney, RJ
    Mo, RW
    Meyer, DT
    Wang, L
    Yao, WQ
    Wasserman, ZR
    Liu, RQ
    Covington, MB
    Tortorella, MD
    Arner, EC
    Qian, MX
    Christ, DD
    Trzaskos, JM
    Newton, RC
    Magolda, RL
    Decicco, CP
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (07) : 1297 - 1300
  • [29] Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety
    Adang, AEP
    Lucas, H
    de Man, APA
    Engh, RA
    Grootenhuis, PDJ
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (24) : 3603 - 3608
  • [30] Azaindoles: Moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors
    Sanderson, PEJ
    Stanton, MG
    Dorsey, BD
    Lyle, TA
    McDonough, C
    Sanders, WM
    Savage, KL
    Naylor-Olsen, AM
    Krueger, JA
    Lewis, SD
    Lucas, BJ
    Lynch, JJ
    Yan, YW
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (05) : 795 - 798